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term follow up in Heart Failure (HF) patients. However, whether Gal-3 is 
related to cardiac remodeling and outcome after long term follow up is currently 
unknown. Therefore we determined the utility of  Gal-3 as a novel biomarker 
for left ventricular remodeling and long-term outcome in patients with severe 
chronic HF.
Methods and Results: A total of  240 HF patients with New York Heart 
Association (NYHA) Class III and IV were included. Patients were followed for 
8.7±1 years, had a mean age of  71 ± 0.6 years and 73% of  the study population 
was male. Circulating levels of  NT-proBNP and Gal-3 were measured. Serial 
echocardiography was performed at baseline and at 3 months. At baseline 
median Left Ventricular End-Diastolic Volume (LVEDV) was 267 mL [IQR 
232-322]. Patients were divided into three groups according to the change in 
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lower levels of  Gal-3 compared to patients in whom the LVEDV was stable 
















mortality after long term follow up (p=0.001).
Conclusion: Gal-3 is associated with left ventricular remodeling determined by 
serial echocardiography and predicts long-term mortality in patients with severe 
chronic HF.  
Keywords: Heart Failure; Remodeling; Galectin-3
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 Introduction
Heart failure (HF) is one of  the most frequent and challenging medical disorders 
characterized by cardiac remodeling and ventricular dysfunction1. With the 
acknowledgement of  remodeling as a determinant of  disease progression and 
poor prognosis, it has become imperative to identify those patients with the 
highest risk of  adverse outcome. Natriuretic peptides (NPs) can help selecting 
patients at high risk for future events such as rehospitalization for worsening 
HF or death2,3. However, NPs only indicate ventricular loading conditions 
and do not reveal other important mechanisms in HF. In acute HF, sensitivity 
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5,6 and a possible guide for treatment7.
Galectin-3 (Gal-3) is a member of  the Galectin family that binds -galactosides. 
In the failing heart, Gal-3 is produced by macrophages and cardiac 
##8–10. An increase of  Gal-3 stimulates the release of  various mediators, 




deposition and ventricular dysfunction8. In failure-prone hypertrophied rat and 
human hearts8 as well as in patients with acute11,12 and chronic HF13,15, increased 
plasma levels of  Gal-3 were detected. Taken together, these observations suggest 
that circulating Gal-3 is useful in identifying patients at risk for developing cardiac 
remodeling and consequently, poor prognosis.
We hypothesized that Gal-3 levels are especially elevated in those patients with 
HF and remodeling of  the left ventricle, determined by serial echocardiography, 
compared to Gal-3 levels of  HF patients without remodeling.
 Methods
Study population


















18. The main exclusion criteria were an expected 
survival of  less than 1 year and planned hospitalization. 
Almost all patients (97%) had a left ventricular systolic dysfunction with a 
reduced ejection fraction (HFrEF) with a mean ejection fraction of  31 %. The 
study was approved by the local Medical Ethics Committees and complied with 












second echocardiography could be performed. It was impossible to measure a 
left ventricular end-diastolic volume (LVEDV) in 38 patients (16%) due to poor 
image quality and in 8 patients (3%) either Gal-3 levels and/or NT-proBNP 
were missing or were lost to follow-up. A total of  182 patients with a complete 
dataset of  serial echocardiography was analysed. Standard parasternal, apical 
three-chamber and apical four-chamber views were performed at baseline and 
after 3 months of  follow-up. A Philips Sonos 5500 or a Philips NZE28 Sonos 
7500-Live 3D echo machine was used. Each patient was analysed with the same 
echo machine to limit variability. Two investigators performed and analysed the 
echocardiographic data. Calculation of  LVEDV, left ventricular end-systolic 
volume and ejection fraction (EF) was performed by using the Teichholz-
method 19. Two investigators blinded to the Gal-3 data and outcome analysed 
all data. The degree of  LV remodeling was assessed according to the change 
in LVEDV between baseline and after 3 months of  follow-up, expressed as a 
percentage of  the baseline measurement. According to previous published 
studies 20,21, we divided patients into three categories according to the change in 
LVEDV: decrease in LVEDV <8 %, stable LVEDV 8–8 %) and an increase in 
LVEDV >8 %.
Laboratory assessment
A complete dataset of  232 patients was available for evaluation of  plasma 
NT-proBNP and Gal-3 levels. Plasma was collected in chilled in disposable tubes, 
containing aprotinin. After centrifugation at 4 °C, plasma samples were stored at 70 
°C. NT-proBNP levels were determined by an immunoelectrochemiluminesence 
method (Elecsys; Roche Diagnostics, Basel, Switzerland). Plasma Gal-3 levels 
were determined using an optimized ELISA kit (BG Medicine, Waltham, USA) 
and were measured on a Bio-tekELx800 microplate reader (Biotek Instruments, 
Winooski, USA). Calibration of  the assay was performed according to the 
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Cockroft Gault equation). This formula is validated in chronic HF patients23.
Statistical analyses
Data are given as mean ± SEM when normally distributed, as median and 
interquartile range (IQR) when skewed, and as frequencies for categorical 
variables. We compared differences between groups with the Mann–Whitney U 
test, student’s t test, Kruskal–Wallis test or ANOVA with LSD post hoc testing 
where appropriate. Non-normally distributed continuous variables were 
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log-transformed and normal distribution was checked thereafter. Gal-3 values 
were categorized into quartiles based upon their distribution among all patients 
and a Kaplan–Meier product limit analysis was performed. For mortality analysis, 
we used the complete cohort of  232 patients, since this increased the power and 
did not compromise the Cox-regression analysis. The log-rank test was used to 
test equality of  estimated survival distribution functions across quartiles of  Gal-
3. In addition, the association between Gal-3 levels and the instantaneous relative 
risk of  death from any cause was analysed using a Cox proportional hazards 
regression analysis and Kaplan–Meier product limit estimation. An univariate 





associated with baseline Gal-3 value and death from any cause. Gal-3 values were 
examined continuously [expressed per standard deviation (SD)]. Furthermore, 
we assessed the association between change in Gal-3 levels between 3 months 
and baseline and 12 months and baseline. The variables Gal-3, age, sex, baseline 
LVEDV, NYHA class, eGFR, NT-proBNP, etiology of  HF and duration of  










stepwise in a multivariable linear regression model on the basis of  the strength of  









in ROC analyses, the best prognosticators for the primary endpoints were 
















statistical analysis, SPSS version 16.0 was used
 Results
Baseline characteristics of  the total cohort have been published previously16. In 
short, the mean age of  the total cohort was 71 ± 0.6 years, 73 % of  the study 
population was male, 30 % had diabetes mellitus and in 63 % of  the patients 
ischemia was the primary cause of  HF (Table 1). The mean follow-up was 8.7 
± 1 year. Data of  the echocardiography sub-population (n = 182) are shown in 
Table 2.
LV-remodeling and Gal-3
Forty-six patients (25 %) showed a regression of  their LVEDV of  more than 8 
%, whereas 108 patients (59 %) had a stable LVEDV and 28 patients (15 %) had 
an increase of  more than 8 % in LVEDV. Variables associated with the degree of  
remodeling are shown in Table 1. In order to investigate whether Gal-3 
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Table1.  Change in LEDV and baseline characteristics
      
 Change in LVEDV
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Table 2.   Baseline Echocardiography data
  Change in LVEDV
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LVEDD = Left ventricular End Diastolic Diameter; LVESD= Left Ventricular End Systolic Diameter; LVEDV = 
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MR = Mitral Valve Regurgitation






















































































































































































































































































































































































































































































































































































































































































































































































levels were related to baseline LVEDV, we divided the total patient cohort into 
quartiles divided by the LVEDV (Table 3). No differences in Gal-3 levels could 
be observed between the different quartiles (p = 0.60). In addition, LVEDV did 
not correlate to Gal-3 (r = 0.08, p = 0.28).
Receiver operating characteristic curve analysis revealed that Gal-3 was able to 
predict regression of  the LVEDV with an area under the curve (AUC) of  0.66 
[0.57–0.74] (p = 0.002). In contrast, NT-proBNP did not predict remodeling 
with an AUC of  0.572 [0.48–0.66] (p = 0.14; data not shown).
Factors with univariable association (p < 0.15) with change in LVEDV including 
baseline LVEDV, Gal-3 levels, sex, etiology of  HF, NYHA-class and duration of  












To assess whether serial measurements of  Gal-3 could predict regression of  the 
LVEDV, ROC curves with both Gal-3 at 3 months and 1 year were calculated. 
The ROC analysis for Gal-3 at 3 months revealed an AUC of  0.62 (p = 0.03), 
while the AUC of  Gal-3 at 1-year follow-up was 0.61 (p = 0.05; data not shown). 
This indicates that a single measurement at baseline was at least as good as 
serial measurements. In addition, there was no correlation between change in 
Gal-3 levels (3 months-baseline and 1 year-baseline) and change in LVEDV 
(r = 0.044, p = 0.56 and r = 0.057, p = 0.48, respectively).
Clinical endpoints
During follow-up of  the total cohort (n = 240), 162 patients died (68 %). The 
mean follow-up of  the surviving patients was 8.7 ± 1.0 years; three patients were 
lost to follow-up. As expected, Kaplan–Meier analysis revealed that an increase 
of  the LVEDV was associated with a higher mortality rate (log-rank, p = 0.01; 
Fig. 2). Baseline Gal-3 levels were associated with mortality during long-term 
follow-up. Figure 3 shows the Kaplan–Meier survival curve according to the 












adjusted for age, gender, NT-proBNP and renal function.
Discussion
During follow-up of  the total cohort (n = 240), 162 patients died (68 %). The 
mean follow-up of  the surviving patients was 8.7 ± 1.0 years; three patients were 
lost to follow-up. As expected, Kaplan–Meier analysis revealed that an increase 
of  the LVEDV was associated with a higher mortality rate (log-rank, p = 0.01; 
Fig. 2). Baseline Gal-3 levels were associated with mortality during long-term 
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follow-up. Figure 3 shows the Kaplan–Meier survival curve according to the 












adjusted for age, gender, NT-proBNP and renal function.
Limitations
There are several limitations related to our study. Major limitations are its relatively 
small size and the lack of  other endpoints besides all-cause mortality. However, 
since all patients were at least in NYHA III, it is expected that in the vast majority 
of  the patients died of  a cardiovascular cause. Another limitation is that almost 
(97 %) patients had a reduced ejection fraction (HFrEF) and were in NYHA 
class III. Therefore, our data cannot be extrapolated to patients with HFpEF 
and NYHA class II. Furthermore, we performed echocardiography at baseline 
and 3 months. This is a rather short interval, however, since this is a severe HF 
population, extending this period would lead to the loss of  follow-up of  a larger 
proportion of  patients, reducing the power of  our analysis. In this 3-month 
period, already 12 patients (5 %) died before the second echocardiography could 
be performed.




the effect of  aldosterone antagonist treatment in relation to Gal-3 levels and 
subsequent remodeling would be valuable to evaluate in a prospective trial.
 Conclusion
We demonstrate that Gal-3 predicts remodeling of  the left ventricle in patients 
with severe chronic HF, whereas NT-proBNP does not. This relation is 
independent to other known risk factors for LV remodeling. In addition we show 
that Gal-3 predicts mortality after long-term follow-up.
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Gal-3 and NT-proBNP levels according to cardiac remodeling. 
Decrease in LVEDV (>8 % decrease in LVEDV compared to baseline), Stable 
LVEDV (change in LVEDV between -8% and 8% compared to baseline), 
Increase LVEDV (>8% increase in LVEDV compared to baseline). 
Data are presented as median and interquartile range (IQR).
Figure 2
Kaplan-Meier survival curves according to the degree of  remodeling. Decrease 
in LVEDV (>8 % decrease in LVEDV compared to baseline), Stable LVEDV 
(change in LVEDV between -8% and 8% compared to baseline), Increase 
LVEDV (>8% increase in LVEDV compared to baseline).
Figure 3
Kaplan-Meier survival curves according to the quartiles of  Gal-3 levels measured 
at baseline (Q1: Gal-3 < 13.5 ng/mL Q2: Gal-3 13.6-17.6 ng/mL; Q3 Gal-3 
17.7-21.6 ng/mL; Q4 Gal-3 >21.7 ng/mL.)
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Figure 1
Gal-3 and NT-proBNP levels according to cardiac remodeling. 
-Decrease in LVEDV (>8 % decrease in LVEDV compared to baseline) 
-Stable LVEDV (change in LVEDV between -8% and 8% compared to baseline)
-Increase LVEDV (>8% increase in LVEDV compared to baseline) 
Data are presented as median and interquartile range (IQR).
Figure 2
Kaplan–Meier survival curves according to the degree of  remodeling. Decrease 
in LVEDV (>8 % decrease in LVEDV compared to baseline), Stable LVEDV 
(change in LVEDV between 8 and 8 % compared to baseline), Increase LVEDV 





Kaplan-Meier survival curves according to the quartiles of  Gal-3 levels measured 
at baseline (Q1: Gal-3 < 13.5 ng/mL Q2: Gal-3 13.6-17.6 ng/mL; Q3 Gal-3 
17.7-21.6 ng/mL; Q4 Gal-3 >21.7 ng/mL.)
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